Who is sponsoring NCT06727058?

NCT06727058 is sponsored by Sanofi Pasteur, a Sanofi Company.

What drugs are being tested in NCT06727058?

Interventions in NCT06727058: Pandemic flu H5 mRNA vaccine, Placebo.

What condition does NCT06727058 study?

NCT06727058 studies Influenza Immunization.

Is NCT06727058 still recruiting?

NCT06727058 is currently active, enrolled. Last updated 21 January 2026.

Last reviewed 2026-01-21 · How we verify

NCT06727058

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study to Evaluate Safety and Immunogenicity of a Pandemic Flu H5 mRNA Vaccine in Healthy Adults Aged 18 Years and Older

Active, enrolled Phase 1, PHASE2 Last updated 21 January 2026

What this trial tests

Phase 1, PHASE2 trial testing Pandemic flu H5 mRNA vaccine in Influenza Immunization in 276 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

9 December 2024

Primary endpoint
31 March 2026

31 March 2026

Quick facts

Lead sponsor	Sanofi Pasteur, a Sanofi Company
Phase	Phase 1, PHASE2
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	randomized
Design	sequential
Masking	triple
Primary purpose	prevention
Enrollment	276
Start date	9 December 2024
Primary completion	31 March 2026
Estimated completion	31 March 2026
Sites	14 locations across United States

Drugs / interventions tested

Pandemic flu H5 mRNA vaccine — full drug profile →
Placebo

Conditions studied

Influenza Immunization — all drugs for Influenza Immunization →

Sponsor

Sanofi Pasteur, a Sanofi Company — full company profile →

Who can join

18 and older, any sex, with Influenza Immunization. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate a pandemic flu H5 strain messenger ribonucleic acid (mRNA) vaccine at 3 dose levels (low, medium, and high) in comparison with placebo in 276 healthy adult participants to select the adequate dose for further clinical development. The duration per participant will be approximately 13 months.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

mRNA Vaccine Technology Beyond COVID-19.
Oloruntimehin S, Akinyi F, Paul M, Ariyo O. · · 2025 · cited 2× · PMID 40573932 · DOI 10.3390/vaccines13060601

Verify or expand the search:

Other recruiting trials for Influenza Immunization

Currently open trials in the same condition.

NCT06695117 — Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombin · Phase 1, PHASE2 · active not recruiting
NCT06695130 — Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombin · Phase 1, PHASE2 · active not recruiting

Other Sanofi Pasteur, a Sanofi Company trials

Trials by the same sponsor.

NCT07536048 — A Longitudinal Study of Epstein-Barr Virus (EBV) Reactivation in Adults Aged 18 to 29 Years · not yet recruiting
NCT07222059 — Phase 3 Single Arm, Open Study on vYF in Adults · Phase 3 · completed
NCT07013747 — Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Participants With Mild Acne · Phase 1, PHASE2 · recruiting
NCT06838000 — Study of the Safety and Immunogenicity of Catch-up Vaccination With a 21-valent Pneumococcal Conjugate Vaccine (PCV21) i · Phase 3 · active not recruiting
NCT06793826 — Post-marketing Surveillance Study for the Safety of a DTaP-IPV- HB-PRP~T Vaccine in Republic of Korea · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06727058 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sanofi Pasteur, a Sanofi Company
Last refreshed: 21 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06727058.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing